溶瘤生物科技 ONCY 深 滬
已收盤 05-08 16:00:00 美东时间
0.8899
-0.010
-1.12%
華盛通- 最 高0.9019
- 今 開0.89
- 成交量 63.38万股
- 最 低 0.8721
- 昨 收 0.90
- 總市值 1.03亿
- 52周最高 1.51
- 市盈率 靜 --
- 換手率 0.55%
- 52周最低 0.3258
- 委 比 -33.33%
- 總股本 1.16亿
- 歷史最高 6.037
- 量 比 0.51
- 振 幅 3.31%
- 歷史最低 0.3258
- 每 手 1
- 風險率 0.24%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Oncolytics Biotech Announces Its Data From REO 022 Trial In Metastatic Colorectal Cancer Shows 19.5-Month Median Duration Of Response In Second-Line KRAS-Mutant MSS mCRC Participants
Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage company developing pelareorep, an investigational, systemically delivered immunotherapy that has been shown to activate innate
05-04 21:02
Oncolytics Biotech Aligns With FDA On Pivotal Trial Design For Pelareorep In Advanced Anal Cancer
Company to leverage strong durability and survival data in second-line and later metastatic squamous cell anal carcinomaPivotal study expected to focus on patients in a post-standard-of-care patient population with no
04-27 20:11
Oncolytics Biotech Establishes $75 Million ATM Offering
Oncolytics Biotech ( ($ONCY) ) just unveiled an announcement. On April 6, 2026,...
04-07 04:28
Oncolytics Biotech Schedules FDA Type C Meeting On April 16
Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, an investigational, systemically delivered immunotherapy that has been shown to
04-06 21:03
Oncolytics Biotech® Completes Domicile Change to the United States
Oncolytics Biotech Inc., a clinical-stage immunotherapy company, completed its jurisdiction of incorporation change from Alberta, Canada, to Nevada, USA. The move, approved by shareholders in January 2026, was finalized on March 31, 2026. San Diego will now serve as the company's headquarters, while Calgary will retain an office. The company expects benefits such as operational efficiency and better access to U.S. capital markets. The common stoc...
04-01 13:00
Geron appoints Patricia S. Andrews and Constantine Chinoporos to board of directors
Geron appoints Patricia S. Andrews and Constantine Chinoporos to board of directors Geron appointed Patricia S. Andrews and Constantine Chinoporos to its board of directors. Patricia Andrews is a board member at Glenmark Pharmaceuticals and Oncolytics Biotech, and previously served as CEO of Sumitom
03-26 20:04
Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026
Pelareorep, an investigational immunotherapy, activates immune responses and promotes tertiary lymphoid structure formation, enhancing treatment efficacy in RAS-driven tumors. Clinical data show improved response rates in breast and gastrointestinal cancers. Ongoing studies, including the GOBLET trial and AWARE-1, demonstrate pelareorep's potential to convert "cold" tumors into "hot" ones, making them more responsive to immunotherapy. These find...
03-19 13:00
Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion
Issued on behalf of Oncolytics Biotech Inc. USANewsGroup.com News Commentary VANCOUVER, BC, March 3, 2026 /PRNewswire/ --The global oncology market is projected to nearly triple from $279.9...
03-03 22:00
Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Feb. 25, 2026 /PRNewswire/ -- Equity Insider News Commentary, The immuno-oncology market is forecast to grow from $65.22 billion in...
02-25 22:00
Oncolytics Biotech gains as enrollments for GIT cancer trial conclude
Oncolytics Biotech (ONCY) traded higher on Tuesday after the Canadian biotech company announced that it has decided to end enrollment in its Phase 1/2 GOBLET study for a drug regimen comprising pelare...
02-25 03:45
